EGFR Expression After Chemotherapy in Colorectal Cancer
Author Information
Author(s): Khalifa Mahmoud A, Rowsell Corwyn H, Gladdy Rebecca, Ko Yoo-Joung, Hanna Sherif, Smith Andy, Law Calvin
Primary Institution: Sunnybrook Health Sciences Center
Hypothesis
Does postoperative chemotherapy affect the EGFR expression in colorectal adenocarcinoma recurrences?
Conclusion
Recurrences after chemotherapy are likely to have lower EGFR expression compared to those who did not receive chemotherapy.
Supporting Evidence
- 63.6% of primary tumors had positive EGFR immunostaining.
- 57.6% of cases showed the same EGFR status in both primary and recurrent tumors.
- Patients receiving chemotherapy had an odds ratio of 4.75 for lower EGFR levels.
Takeaway
This study looked at how chemotherapy affects a specific protein in colorectal cancer. It found that patients who had chemotherapy might have less of this protein in their cancer when it comes back.
Methodology
The study involved 33 patients with colorectal adenocarcinoma, comparing EGFR expression in primary and recurrent tumors after chemotherapy.
Limitations
The study is limited by a small sample size.
Participant Demographics
{"age_range":"41 to 80","mean_age":65.4,"sex_distribution":{"males":11,"females":7}}
Statistical Information
P-Value
0.6598
Confidence Interval
0.94 – 26.73
Statistical Significance
p = 0.6598
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website